Compositions and Methods for Increasing Immunogenicity of Glycoprotein Vaccines
20190262446 ยท 2019-08-29
Inventors
Cpc classification
C12N7/00
CHEMISTRY; METALLURGY
C12N2760/16134
CHEMISTRY; METALLURGY
C12N2760/16152
CHEMISTRY; METALLURGY
C12N2760/16122
CHEMISTRY; METALLURGY
C12Y302/01018
CHEMISTRY; METALLURGY
C12Y204/01087
CHEMISTRY; METALLURGY
C12N9/1081
CHEMISTRY; METALLURGY
C12N2760/16252
CHEMISTRY; METALLURGY
C12N2760/16222
CHEMISTRY; METALLURGY
International classification
Abstract
The present invention relates to the microbial immunogens engineered to bear -gal epitope(s) for induction of potent humoral and cellular immune responses when administered to subjects having anti-Gal antibodies. In one embodiment, the present invention provides compositions and methods for propagating influenza virus in human, ape, Old World monkey or bird cells that have been engineered to express an 1,3galactosyltransferase ( 1,3GT) gene to produce virions bearing hemagglutinin molecules containing -gal epitopes, to increase the immunogenicity of the influenza virus. In another embodiment, the present invention provides fusion proteins between influenza virus hemagglutinin and a microbial peptide or protein of interest, and enzymatic processing of this fusion protein to carry -gal epitopes, to increase the immunogenicity of the microbial peptide or protein of interest.
Claims
1. A method, comprising: a) providing; i) an influenza virus; and ii) a host cell susceptible to infection by said influenza virus and comprising an expression vector comprising a nucleic acid encoding an 1,3galactosyltransferase (1,3gal) in operable combination with a promoter; and b) inoculating said host cell to produce an inoculated host cell, wherein said inoculated host cell produces an influenza virus bearing an -gal epitope (Gal1-3Gal1-4(3)GlcNAc-R).
2. The method of claim 1, wherein said influenza virus is an influenza A virus or an influenza B virus.
3. The method of claim 1, wherein said host cell is selected from the group consisting of a human cell, an ape cell, an Old World monkey cell and a bird cell.
4. The method of claim 3, wherein said Old World monkey cell is a Vero cell.
5. The method of claim 1, wherein said 1,3gal is an enzyme of a species selected from the group consisting of a mouse, a cow, a cat, a sheep, a rat, a pig and a New World monkey.
6. The method of claim 5, wherein said New World monkey is a common marmoset.
7. The method of claim 1, further comprising step c) inactivating said influenza virus bearing an -gal epitope to produce an inactivated influenza virus bearing an -gal epitope.
8. The method of claim 7, further comprising step d) administering said inactivated influenza virus bearing an -gal epitope to a subject having anti-Gal antibodies under conditions suitable for induction of an immune response by said subject.
9. The method of claim 8, wherein said immune response comprises production of antibodies reactive with said influenza virus and T lymphocytes reactive with cells infected by said influenza virus.
10. A composition comprising an isolated host cell susceptible to infection by an influenza virus and comprising an expression vector comprising a nucleic acid encoding an 1,3galactosyltransferase (1,3gal) in operable combination with a promoter.
11. The composition of claim 10, wherein said isolated host cell has little or no sialytransferase activity.
12. The composition of claim 11, wherein said isolated host cell is an inoculated host cell that produces an influenza virus bearing an -gal epitope (Gal1-3Gal1-4(3)GlcNAc-R).
13. The composition of claim 12, wherein said influenza virus is an influenza A virus or an influenza B virus.
14. A method of producing an isolated fusion protein comprising an amino-terminal portion and a carboxy-terminal portion, the method comprising: a) providing recombinant host cells comprising an expression vector, wherein said expression vector comprises a nucleic acid encoding said fusion protein in operable combination with a promoter, and wherein said amino-terminal portion comprises influenza virus hemagglutinin (HA) and said carboxy-terminal portion comprises a protein antigen of interest; b) culturing said recombinant hosts cells to produce said fusion protein; and c) isolating said fusion protein.
15. The method of claim 14, wherein said influenza virus is an influenza A virus or an influenza B virus.
16. The method of claim 14, wherein said protein antigen of interest comprises an influenza virus nucleoprotein.
17. The method of claim 14, wherein said protein antigen of interest comprises an influenza virus M2e oligopeptide.
18. The method of claim 14, further comprising incubating said fusion protein in the presence of neuraminidase, 1,3galactosyltransferase (1,3gal) and UDP-galactose to produce a fusion protein comprising -gal epitopes.
19. The method of claim 14, wherein said transgenic host cell further comprises an expression vector comprising a nucleic acid encoding influenza virus neuraminidase in operable combination with a promoter to effect removal of sialic acid from said fusion protein to produce a sialic acid deficient fusion protein.
20. The method of claim 19, wherein said method further comprises incubating said sialic acid deficient fusion protein in the presence of 1,3galactosyltransferase (1,3gal) and UDP-galactose to produce a fusion protein comprising -gal epitopes.
21. The method of claim 19, wherein said transgenic host cell further comprises an expression vector comprising a nucleic acid encoding an 1,3galactosyltransferase (1,3gal) in operable combination with a promoter to produce a fusion protein comprising -gal epitopes.
22. The fusion protein produced by the method of claim 14.
Description
DESCRIPTION OF THE FIGURES
[0012]
[0013]
[0014]
[0015]
[0016]
[0017]
[0018]
[0019]
[0020]
[0021]
[0022]
[0023]
DEFINITIONS
[0024] To facilitate an understanding of the present invention, a number of terms and phrases are defined below:
[0025] The term -gal epitope as used herein, refers to any molecule, or part of a molecule, with a terminal structure comprising Gal1-3Gal1-4GlcNAc-R, Gal1-3Gal1-3GlcNAc-R, or any carbohydrate chain with terminal Gal1-3Gal at the non-reducing end.
[0026] The term glycolipid as used herein, refers to any molecule with at least one carbohydrate chain linked to a ceramide, a fatty acid chain, or any other lipid. Alternatively, a glycolipid maybe referred to as a glycosphingolipid.
[0027] The term gene refers to a nucleic acid (e.g., DNA) sequence that comprises coding sequences necessary for the production of a polypeptide or precursor or RNA (e.g., tRNA, siRNA, rRNA, etc.). The polypeptide can be encoded by a full length coding sequence or by any portion of the coding sequence so long as the desired activity or functional properties (e.g., enzymatic activity, ligand binding, signal transduction, etc.) of the full-length or fragment are retained. The term also encompasses the coding region of a structural gene and the sequences located adjacent to the coding region on both the 5 and 3 ends, such that the gene corresponds to the length of the full-length mRNA. The sequences that are located 5 of the coding region and which are present on the mRNA are referred to as 5 untranslated sequences. The sequences that are located 3 or downstream of the coding region and that are present on the mRNA are referred to as 3 untranslated sequences. The term gene encompasses both cDNA and genomic forms of a gene. A genomic form or clone of a gene contains the coding region, which may be interrupted with non-coding sequences termed introns or intervening regions or intervening sequences. Introns are removed or spliced out from the nuclear or primary transcript, and are therefore absent in the messenger RNA (mRNA) transcript. The mRNA functions during translation to specify the sequence or order of amino acids in a nascent polypeptide. For instance the term HA gene encompasses the full-length HA nucleotide sequence. However, it is also intended that the term encompass fragments of the HA nucleotide sequence, as well as other domains (e.g., functional domains) within the full-length HA nucleotide sequence. Furthermore, the terms HA gene, HA nucleotide sequence, and HA polynucleotide sequence encompass DNA, cDNA, and RNA sequences.
[0028] As used herein, homology refers to sequence similarity or identity as determined to using standard techniques known in the art (See e.g., Pearson and Lipman, Proc Natl Acad Sci USA, 85:2444, 1988; programs such as GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, Madison, Wis.; and Devereux et al., Nucl Acid Res, 12:387-395, 1984). Sequence similarity determinations are made in part through aligning sequences. A commonly used alignment method is BLAST, although there are other methods that also find use in aligning sequences (Altschul et al., J Mol Biol, 215:403-410, 1990; and Karlin et al., Proc Natl Acad Sci USA, 90:5873-5787, 1993). A particularly useful BLAST program is the WU-BLAST-2 program (See, Altschul et al., Meth Enzymol, 266:460-480, 1996). WU-BLAST-2 uses several search parameters, most of which are set to the default values. The adjustable parameters are set with the following values: overlap span=1, overlap fraction=0.125, word threshold (T)=11. The HSP S and HSP S2 parameters are dynamic values and are established by the program itself depending upon the composition of the particular sequence and composition of the particular database against which the sequence of interest is being searched. However, the values may be adjusted to increase sensitivity. A percent amino acid sequence identity value is determined by the number of matching identical residues divided by the total number of residues of the longer sequence in the aligned region. The longer sequence is the one having the most actual residues in the aligned region (gaps introduced by WU-Blast-2 to maximize the alignment score are ignored). Likewise, percent (%) nucleic acid sequence identity is defined as the percentage of nucleotide residues in a candidate sequence that are identical to the nucleotide residues of the starting sequence (i.e., the sequence of interest).
[0029] A preferred method utilizes the BLASTN module of WU-BLAST-2 set to the default parameters, with overlap span and overlap fraction set to 1 and 0.125, respectively.
[0030] As used herein, the term hybridization refers to the process by which a strand of nucleic acid joins with a complementary strand through base pairing, as known in the art.
[0031] A nucleic acid sequence is considered to be selectively hybridizable to a reference nucleic acid sequence if the two sequences specifically hybridize to one another under moderate to high stringency hybridization and wash conditions. Hybridization conditions are based on the melting temperature (Tm) of the nucleic acid binding complex or probe. For example, maximum stringency typically occurs at about Tm5 C. (5 below the Tm of the probe); high stringency at about 5-10 C. below the Tm; intermediate stringency at about 10-20 C. below the Tm of the probe; and low stringency at about 20-25 C. below the Tm. Functionally, maximum stringency conditions may be used to identify sequences having strict identity or near-strict identity with the hybridization probe; while intermediate or low stringency hybridization can be used to identify or detect polynucleotide sequence homologs.
[0032] Moderate and high stringency hybridization conditions are well known in the art. An example of high stringency conditions includes hybridization at about 42 C. in 50% formamide, 5SSC, 5Denhardt's solution, 0.5% SDS and 100 g/ml denatured carrier DNA followed by washing two times in 2SSC and 0.5% SDS at room temperature and two additional times in 0.1SSC and 0.5% SDS at 42 C. An example of moderate stringent conditions include an overnight incubation at 37 C. in a solution comprising 20% formamide, 5SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5Denhardt's solution, 10% dextran sulfate and 20 mg/ml denatured sheared salmon sperm DNA, followed by washing the filters in 1SSC at about 37-50 C. Those of skill in the art know how to adjust the temperature, ionic strength, etc. as necessary to accommodate factors such as probe length and the like.
[0033] As used herein, the term purified refers to molecules (polynucleotides or polypeptides) that are removed from their natural environment, isolated or separated. Substantially purified molecules are at least 50% free, preferably at least 75% free, more preferably at least 90% and most preferably at least 95% free from other components with which they are naturally associated. Similarly, the term isolated as used herein, refers to any composition or mixture that has undergone a laboratory purification procedure including, but not limited to, extraction, centrifugation and chromatographic separation (e.g., thin layer chromatography or high performance liquid chromatography). Usually such a purification procedures provides an isolated composition or mixture based upon physical, chemical, or electrical potential properties. Depending upon the choice of procedure an isolated composition or mixture may contain other compositions, compounds or mixtures having similar chemical properties.
[0034] The term fusion protein as used herein refers to a protein formed by expression of a hybrid gene made by combining two gene sequences. Typically this is accomplished by cloning a cDNA into an expression vector in frame with an existing gene. The fusion partner may act as a reporter (e.g., gal) or may provide a tool for isolation purposes (e.g., GST).
[0035] The terms alpha-1,3-galactosyltransferase, 1,3GT, glycoprotein alpha-galactosyltransferase 1 and GGTA1, as used herein refer to any enzyme capable of synthesizing -gal epitopes. The enzyme is expressed in most mammals with the exception of humans, apes and Old World monkeys. The carbohydrate structure produced by the enzyme is immunogenic in man and most healthy people have high titer natural anti -gal antibodies. In some embodiments, the term 1,3GT refers to a common marmoset gene (e.g., Calllthrix jacchusGENBANK Accession No. S71333) and its gene product, as well as its functional mammalian counterparts (e.g., other New World monkeys, prosimians and non-primate mammals, but not Old World monkeys, apes and humans). The marmoset 1,3GT coding region is set forth as SEQ ID NO: 1, while the marmoset 1,3GT protein sequence is set forth as SEQ ID NO:2. Moreover, the mouse 1,3GT coding sequence is set forth as SEQ ID NO:3 (e.g., Mus musculusnucleotides 445 to 1560 of GENBANK Accession No. NM_010283), while the mouse 1,3GT protein sequence is set forth as SEQ ID NO:4. Other non-primate mammalian 1,3GT enzymes include but are not limited to bovine 1,3GT (e.g., Bos taurusGENBANK Accession No. NM_177511), feline 1,3GT (e.g., Felis calusGENBANK Accession No. NM_001009308), ovine 1,3GT (e.g., Ovis ariesGENBANK Accession No. NM_001009764), rat 1,3GT (e.g., Rattus norvegicusGENBANK Accession No. NM_145674) and porcine 1,3GT (e.g., Sus scrofaGENBANK Accession No. NM_213810). Some embodiments of the present invention comprise a functional variant of a mammalian 1,3GT, which differs from the wild type mammalian 1,3GT sequences in, for example, fewer than 1-5% of the residues. In particular, 1,3GT variants include but are not limited to naturally occurring functional mammalian 1,3GT variants, as well as non-naturally occurring variants generated by recombinant or other means (e.g., 1, 2, 3, 4 or 5 amino acid substitutions, deletions, or additions, preferably corresponding to a residue from a functional mammalian 1,3GT homolog) are contemplated to find use in the compositions and methods of the present invention. In other embodiments, truncated forms of a mammalian 1,3GT, which retain catalytic activity, are employed (e.g., GGTA1 lacking 90 amino acid N-terminal stem region).
[0036] The term anti-Gal binding epitope, as used herein, refers to any molecule or part of molecule that is capable of binding in vivo the natural anti-Gal antibody.
[0037] The term vaccine as used herein, refers to a composition that is administered to produce or artificially increase an immune response to an immunogen. For example, vaccine compositions frequently comprise a preparation of killed or live attenuated microorganisms. Alternatively, subunit vaccines frequently comprise a preparation of isolated nucleic acids or proteins corresponding to the genes or gene products of a microorganism of interest.
[0038] The term route as used herein, refers to methods for administration of a prophylactic or therapeutic agent. In some embodiments, route refers to the method of administration of a vaccine including but not limited to intramuscular, intravenous, intraperitoneal, subcutaneous, oral, intranasal, intravaginal, intrarectal, and stomacheal administration methods.
[0039] As used herein, the term physiologically acceptable solution refers to an isotonic solution such as an aqueous solution comprising for example, saline, phosphate buffered saline, Hanks' solution, or Ringer's solution.
[0040] As used herein, the term immune response refers to the reactivity of a subject's immune system in response to an antigen. In mammals, this may involve antibody production, induction of cell-mediated immunity, and/or complement activation. The term immune response encompasses but is not limited to one or more of a lymphocyte proliferative response, a cytokine response, an antibody response, and a cytotoxic T lymphocyte response.
[0041] The term reactive with an antigen of interest when made in reference to an immune response refers to an increased level of the immune response to the antigen of interest (e.g., flu virus) as compared to the level of the immune response to a control (e.g., irrelevant antigen).
[0042] The term lymphocyte proliferative response refers to antigen-induced increase in lymphocyte numbers. Alternatively, or in addition, the term proliferation refers to the physiological and morphological progression of changes that cells undergo when dividing, for instance including DNA replication as measured by tritiated thymidine incorporation.
[0043] The term cytokine response refers to antigen-induced cytokine secretion by lymphocytes as measured for instance by assaying culture supernatants for cytokine content (e.g., IL-2, IFN, TNF, IL-4, etc) by ELISA.
[0044] The term antibody response refers to the production of antibodies (e.g., IgM, IgA, IgG) that bind to an antigen of interest (e.g., flu virus), this response is measured for instance by assaying sera by ELISA.
[0045] As used herein, the term antibodies reactive with refers to antibodies that bind to an antigen of interest. In preferred embodiments, the term antibodies reactive with is used in reference to antibodies that bind to a virus of interest (or to a viral protein).
[0046] The term cytotoxic T lymphocytes reactive with refers to cytotoxic T lymphocytes capable of lysing an MHC (e.g., HLA)-matched cell presenting epitopes derived from an antigen of interest. In preferred embodiments, the term cytotoxic T lymphocytes reactive with is used in reference to cytotoxic T lymphocytes or CTLs capable of lysing a MHC-matched cell infected by a virus of interest, or presenting epitopes derived from viral proteins.
[0047] The term helper T lymphocytes reactive with refers to helper T lymphocytes capable of secreting lymphokines in response to an MHC (e.g., HLA)-matched cell presenting epitopes derived from an antigen of interest. In preferred embodiments, the term helper T lymphocytes reactive with is used in reference to helper T lymphocytes or T.sub.H cells capable of secreting lymphokines in response to an MHC-matched cell infected by the virus of interest, or presenting epitopes derived from viral proteins.
[0048] The term adjuvant as used herein refers to any compound that when injected together with an antigen, non-specifically enhances the immune response to that antigen. Exemplary adjuvants include but are not limited to incomplete Freunds adjuvant (IFA), aluminum-based adjuvants (e.g., AlOH, AlPO4, etc), and Montanide ISA 720.
[0049] The terms excipient, carrier and vehicle as used herein refer to usually inactive accessory substances into which a pharmaceutical substance (e.g., inactivated flu virus) is suspended. Exemplary carriers include liquid carriers (such as water, saline, culture medium, aqueous dextrose, and glycols) and solid carriers (such as carbohydrates exemplified by starch, glucose, lactose, sucrose, and dextrans, anti-oxidants exemplified by ascorbic acid and glutathione, and hydrolyzed proteins).
[0050] The terms mammals and mammalian refer to animals of the class mammalian that nourish their young by fluid secreted from mammary glands of the mother, including human beings. The class mammalian includes placental animals, marsupial animals, and monotrematal animals.
[0051] The term control refers to subjects or samples which provide a basis for comparison for experimental subjects or samples. For instance, the use of control subjects or samples permits determinations to be made regarding the efficacy of experimental procedures. In some embodiments, the term control subject refers to animals, which receive a mock treatment (e.g., inactivated flu virus lacking anti-Gal epitopes).
GENERAL DESCRIPTION OF THE INVENTION
[0052] The present invention relates to the field of microbial vaccines in general and influenza virus vaccines in particular. In particular the present invention provides compositions and methods for induction of a potent immune response by targeting a microbial antigen of interest to antigen presenting cells (APC) of a recipient. As described herein, this targeting is achieved by exploiting the natural anti-Gal antibody, which is the most abundant natural antibody in humans constituting 1% of immunoglobulins. This antibody interacts specifically with the carbohydrate epitope called the -gal epitope with the structure Gal1-3Gal1-4GlcNAc-R, or Gal1-3Gal1-3GlcNAc-R. In one embodiment, the invention provides methods of propagating vaccine flu virus in bird, human, ape or Old World monkey cells (e.g., Vero cells) that are engineered to synthesize -gal epitopes by stable transfection of the cells with the 1,3galactosyltransferase (1,3GT) gene and selection for cells that have high activity of this gene. The present invention also provides methods of administering flu virus expressing -gal epitopes (flu.sub.gal) to a subject having anti-Gal antibodies, which results in effective anti-Gal targeting of the flu virus to APC. In further embodiments, the present invention provides immunogens comprising a fusion between an N-linked glycoprotein (e.g., influenza virus hemagglutinin) and a polypeptide antigen of interest (e.g., microbial peptide or protein), and enzymatic processing of the fusion protein to carry -gal epitopes. In one embodiment, the immunogen comprises of a fusion protein between influenza virus hemagglutinin and the influenza virus peptide M2e, and enzymatic processing of this fusion protein to carry -gal epitopes, in order to elicit humoral immune responses in subjects having anti-Gal antibodies. In one embodiment, the immunogen comprises of a fusion protein between influenza virus hemagglutinin and the influenza virus nucleoprotein (NP), and enzymatic processing of this fusion protein to carry -gal epitopes, in order to elicit a cellular immune response in subjects having anti-Gal antibodies.
DETAILED DESCRIPTION OF THE INVENTION
[0053] As described herein, the present invention provides methods and compositions for increasing the immunogenicity of inactivated flu virus immunogens (also referred to as subunit flu vaccines) through the production of influenza virus expressing -gal epitopes in a cell line (e.g., Vero cell line) engineered to express high levels of the glycosylation enzyme 1,3galactosyltransferase (1,3GT). This ensures effective anti-Gal mediated targeting of influenza virus to antigen presenting cells (APC) of a vaccine recipient. The present invention also provides methods and compositions for using influenza virus hemagglutinin (HA) as a platform for targeting protein antigens of interest (e.g., M2e and NP) to APC. In exemplary embodiments, this is achieved by production of recombinant fusion proteins between HA and M2e (HA-M2e) and between HA and NP (HA-NP), and by synthesis of -gal epitopes on the HA portion of these fusion proteins. The -gal epitopes on the HA portion of these recombinant proteins bind anti-Gal, which effectively targets these immunogens to APC resulting in the induction of potent immune responses to HA and M2e or HA and NP in subjects having endogenous anti-Gal antibodies.
[0054] I. Targeting Antigens to Antigen Presenting Cells (APC)
[0055] In general, a prerequisite for efficacy of a flu vaccine is the effective uptake of inactivated flu virus at the inoculation site by APC (e.g., dendritic cells and macrophages). In general, this prerequisite applies to influenza virus subunit vaccines comprising HA and NA, as well as other types of recombinant protein vaccines. APC internalizing the subunit vaccine transport it from the vaccination site to draining lymph nodes, where they present the immunogenic viral peptides on cell surface MHC class I and class II molecules for the activation of virus specific CD8+ and CD4+ T cells respectively (Zinkiernagel et al., Immunol Rev 156:1.1997). Activated CD4+ T cells are essential as helper T cells (Th cells) for providing help to virus specific B cells for the production of anti-viral antibodies. The Th cells further provide help to CD8+ T cells to become CTL that specifically destroy flu virus infected cells. Since currently used flu vaccines lack markers that identify them for uptake by APC at the vaccination site, the uptake of these subunit vaccines by APC is suboptimal as it is primarily mediated by random pynocytosis.
[0056] One of the most effective methods for active in situ targeting of vaccines to APC is by formation of immune complexes with the corresponding IgG molecules (e.g., opsonization). This targeting occurs because APC (including dendritic cells, Langerhans cells of the skin and macrophages) all express FcR for the Fc portion of the antigen bound IgG antibody (Unkeless, J Clin Inves 83:355, 1989; and Clynes et al., Proc Natl Acad Sci USA 95:652, 1998). This interaction between the Fc portion of the opsonizing antibodies and FcR on APC is considered the most effective mechanism by which APC identify and internalize antigens for induction of a robust immune response (Regnault et al., J Exp Med 189:371, 1999). Accordingly, administration of vaccinating antigens in the form of immune complexes was found to increase immunogenicity by 10-1000 fold, with tetanus toxoid (Manca et al., J Exp Med 173:37, 1991), hepatitis B antigen (Celis and Chang, Science 224:297, 1984), Eastern equine encephalomyelitis virus (Houston et al., J Infect Dis 135:600, 1977) and simian immunodeficiency virus (Villinger et al., J Virol 77:10, 2003). The present invention exploits the natural anti-Gal antibody for targeting of flu vaccines to APC of humans, apes, Old World primates and birds, thereby increasing their efficacy in eliciting both specific and cross-protective immune responses.
[0057] II. Anti-Gal Mediated Targeting of Antigens to APC
[0058] Anti-Gal is a unique natural antibody that is the most abundant antibody in humans constituting 1% of serum IgG (20-100 g/ml) (Galili et al., J Exp Med 160:1519, 1984). This antibody interacts specifically with the -gal epitope (Gal1-3Gal1-4GlcNAc-R or Gal1-3Gal1-3GlcNAc-R) on glycolipids and glycoproteins (Galili. Springer Semin Immunopathol 15:155, 1993). Anti-Gal is produced throughout life as a result of antigenic stimulation by bacteria of the gastrointestinal flora (Galili et al., Infect Immun 56:1730, 1988). The -gal epitope is absent in humans, but is synthesized by the glycosylation enzyme 1,3galactosyltransferase (1,3GT) in very large amounts in cells of non-primate mammals, prosimians and in New World monkeys (Galili et al., J Biol Chem. 263:17755, 1988). The 1,3GT gene was inactivated in ancestral Old World primates. Thus, humans, apes, and Old World monkeys all lack -gal epitopes, but produce the anti-Gal antibody in large amounts (Galili, supra, 1993). Anti-Gal binds avidly in vivo to -gal epitopes introduced into humans, or Old World monkeys. This is particularly evident in xenotransplantation, where the in vivo binding of anti-Gal to -gal epitopes on transplanted pig heart or kidney is the main cause for the rapid rejection of such grafts in humans and in Old World monkeys (Galili, Immunol Today 14:480, 1993; and Collins et al., J Immunol 154:5500, 1995). This in situ interaction of anti-Gal with -gal epitopes can be exploited for targeting viral envelope glycoproteins to APC. In fact, anti-Gal is the only antibody in humans that can serve for the purpose of targeting antigens to APC, because it is the only natural antibody known to be produced ubiquitously in large amounts in all humans (Galili, supra. 1993). Thus, any particulate or soluble antigen that has -gal epitopes will form immune complexes with anti-Gal and will be targeted for effective uptake by APC (Galili, Immunol Cell Biol 83:674, 2005).
[0059] The immunogenicity of recombinant viral proteins expressing -gal epitopes is assessed in an experimental animal model, the 1,3GT knockout mouse (KO mouse). Previously, the immunogenicity of a recombinant gp120 protein of the human immunodeficiency virus envelope was observed to increase upon treatment of the recombinant protein with neuraminidase and 1,3GT in vitro to yield an envelope glycoprotein bearing -gal epitopes (Abdel-Motal et al., J Virol 80: 6943, 2006). In particular, a greater than 100 fold higher humoral and cellular immune responses were induced by immunization with a gp120 immunogen bearing -gal epitopes, in comparison with a gp120 immunogen lacking these epitopes (Abdel-Motal et al., supra. 2006). This increased immunogenicity is thought to be achieved through the in vivo formation of immune complexes between anti-Gal and gp120 bearing -gal epitopes (gp120.sub.gal) that are targeted to APC at the inoculation site. These APC transport the internalized envelope glycoprotein to the draining lymph nodes where they present the immunogenic peptides on both MHC class I and class II molecules for the effective activation of CD8+ and CD4+ T cells, respectively. As described in more detailed herein, the present invention provides immunogens comprising an inactivated flu virus, a recombinant HA-M2e fusion protein and/or a recombinant HA-NP to target flu antigens to APC through formation of immune complexes with the natural anti-Gal antibody.
[0060] III. Preparation of Vero.sub.GT Cells for Propagation of Flu.sub.Gal Virus
[0061] The preparation of flu vaccine differs from most other vaccines in clinical use, in that there is a time constraint of only six months from identification of the seasonal HA and NA sequences to vaccine delivery. In the event of a future pandemic outbreak of avian flu virus in human populations, this urgency is even greater because of the lethal outcome of this infection. Thus, the amount of flu vaccine prepared in such a short time period is limited.
[0062] Immunogenicity of vaccines can be maximized by targeting them effectively to APC, in order to enable their transport to lymph nodes, for processing and presentation of peptide epitopes for activation of T cells. Protection afforded by flu vaccines can be greatly increased if they also include a component for induction of a broad cross-protective immune response against conserved viral antigens such as the M2e peptide of the flu M2 protein, and the flu nucleoprotein (NP). As described herein the present invention exploits the existence of natural anti-Gal antibody in human, apes, Old World monkeys and birds, for targeting of the inactivated virus immunogen to APC. For anti-Gal mediated targeting the flu virus immunogen should express multiple -gal epitopes (flu.sub.gal). Injection of inactivated flu.sub.gal in adjuvant results in the in situ binding of natural anti-Gal antibody to the -gal epitopes on the vaccine virus (e.g., opsonization) and targeting of the vaccine to APC as illustrated in
[0063] Recently, much research has been directed toward the use of African green monkey kidney cells (e.g., Vero cell line available as ATCC No. CCL-81) for propagation of 6+2 re-assorted flu virus by reverse genetics, for use in vaccine preparations (Govorkova et al., J Virol 70: 5519, 1996). The interest in propagation of flu virus for vaccine purposes in Vero cells, rather than in the traditional embryonated chicken egg systems, is due in large part to the difficulties in obtaining sufficient numbers of embryonated chicken eggs and to the tendency of flu virus HA to mutate for adaptation of growth in eggs. Thus, the World Health Organization has recommended using the Vero cell line for future production of flu virus immunogens. The flu virus currently used for vaccine preparation lacks -gal epitopes because it is produced in embryonated chicken eggs lacking this epitope, since birds lack the 1,3GT enzyme (Galili et al., J Biol Chem 263:17755, 1988). Vero cells, planned for future propagation of vaccinating flu virus, also lack 1,3GT, since like all Old World monkeys, African green monkeys also lack an active 1,3GT enzyme (Galili supra. 1988).
[0064] Previously it has been shown that when Eastern Equine Encephalitis virus (EEEV) is propagated in the mouse 3T3 fibroblast cell line then the -gal epitope is synthesized within the host cell on the EEEV envelope glycoprotein. In contrast, propagation of EEEV in Vero cells results in the production of an EEEV envelope glycoprotein lacking -gal epitopes (Repik et al., J Gen Virol, 75:1177, 1994). These differences are associated with the production of the 1,3GT enzyme within mouse 3T3 fibroblasts and the absence of the 1,3GT in Vero cells, since the host cell glycosylation machinery synthesizes carbohydrate chains on viral glycoproteins.
[0065] The present invention circumvents the problems associated with the production of a suboptimal flu virus immunogen in cells (e.g., Vero cells) by providing compositions and methods for production of flu.sub.gal without the need for in vitro incubation with 1,3GT and UDP-Gal. For example, this is achieved by propagation of the virus in transgenic Vero cells (or other suitable human, ape or Old World monkey cell line) engineered to express an active 1,3GT enzyme. In some preferred embodiments, cells (e.g., Vero cells) are converted into cells that effectively synthesize -gal epitopes on glycoproteins by heterologous expression of a functional 1,3GT gene (e.g., of a New World monkey or a non-primate mammal).
[0066] The following description uses Vero cells as an example. However, other non-tumorigenic cells lacking microbial contaminants (e.g., reverse transcript negative) could also be employed. Briefly to generate transgenic Vero cells with high 1,3GT activity (referred to as Vero.sub.GT cells) for effective synthesis of -gal epitopes on virus glycoproteins in the Golgi apparatus, the competition from sialyltransferase must be minimized. The final stages in synthesis of carbohydrate chains on glycoproteins and glycolipids take place within the Golgi apparatus, by enzymes called collectively glycosyltransferases. 1,3Galactosyltransferase (1,3GT) and sialyltransferase are two glycosyltransferases that compete with each other within the Golgi apparatus. Specifically these enzymes compete for capping carbohydrate chains with terminal N-acetyllactosamine carbohydrate chains (Gal1-4GlcNAc-R) (See, center carbohydrate chain in
[0067] 1) isolation of Vero cells with low sialyltransferase activity in order to minimize capping of carbohydrate chains by SA thereby increasing their accessibility to 1,3GT within the Golgi apparatus; and
[0068] 2) stable transfection of Vero cells with low sialyltransferase activity with at least one active z1,3GT gene and selection of clones with high 1,3GT activity to maximize capping of carbohydrate chains by of 1,3GT within the Golgi apparatus.
[0069] Vero cells with minimal sialyltransferase activity are selected by sorting of cells that bind a fluorescenated lectin. This lectin (e.g., Datura starmonium lectin) binds specifically to N-acetyllactosamine carbohydrate chains (Gal1-4GlcNAc-R). The sorting may be performed within a cell sorter after cells are incubated with the lectin at decreasing concentrations (of the lectin). The cells binding the lectin at its lowest concentration are those with the highest number of N-acetyllactosamines that are not capped by SA (e.g., cells with the least sialyltransferase activity). These cells are isolated, expanded by incubation in tissue culture medium and transfected (e.g., electroporation) with a 1,3GT expression vector containing an antibiotic resistance gene (e.g., neomycin resistance) for a selection purposes. The transfected cells are grown in presence of a selection agent substance (e.g., G418) to obtain stable transfectants (e.g., transgenic Vero cells containing the 1,3GT gene within their genome. The 1,3GT gene can be any gene encoding an enzyme that synthesizes -gal epitopes (e.g., any non-primate mammalian species). Non-limiting examples of suitable 1,3GT genes include but are not limited to the mouse 1,3GT coding region (GENBANK Accession No. NM_010283) and the pig 1,3GT coding region (GENBANK Accession No. NM_213810). Cells expressing -gal epitopes are cloned by immunostaining with decreasing concentrations of fluoresceinated Bandeiraea similicfolia lectin (BS lectin specific for -gal epitopes) and sorting of cells binding the lectin at the lowest concentration. Other suitable methods for selecting cells expressing -gal epitopes include the immunostaining of cells with decreasing concentrations of a fluoresceinated anti-Gal antibody and sorting of cells binding the antibody at the lowest concentration. In some embodiments, the transgenic Vero cells engineered to express a first heterologous 1,3GT gene are subjected to a second round of transfection with a second expression vector containing the 1,3GT gene and a second selection marker (e.g., hygromycin resistance) and the subsequent growth of the transfected cells in the presence of a second selection agent (e.g., hygromycin). The second selection agent and selection marker can be any selection agent and selection marker that is different from first selection agent and first selection marker employed in the first round of transfection and selection. This transfection and selection process can be repeated one or more times, with each selection increasing the number of copies of heterologous, functional 1,3GT gene in the transfected cells. In certain embodiments, the selected cells expressing -gal epitopes (Vero.sub.GT cells) are grown as individual clones and the clones with the highest expression of -gal epitopes are further expanded.
[0070] The Vero.sub.GT cells are suitable for propagation of flu.sub.gal virus, since the hemagglutinin molecules of flu virus propagated in these cells are subjected to high 1,3GT activity and low sialyltransferase activity in the Golgi apparatus of the transgenic Vero.sub.GT cells. In certain embodiments, the flu.sub.gal virus produced in Vero.sub.GT cells undergoes the same vaccine preparation steps as that currently used for flu virus production in non-transgenic Vero cells (Govorkova et al., J Virol, 70: 5519, 1996). In an exemplary embodiment, the flu virus used to inoculate the Vero.sub.GT cells is a 6+2 re-assortment containing hemagglutinin (HA) and neuraminidase (NA) genes from a vaccine target strain and the remaining genes from A/Puerto Rico/8/34-H1N1 (PR8). In some embodiments, the vaccine target strain is an influenza A virus such as A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/2005 (H3N2) or A/Hiroshima/52/2005 (H3N2), or an influenza B virus such as B/Malaysia/2506/2004 or B/Ohio/1/2005. Other suitable vaccine target strains are listed in the influenza sequence database accessible through the Los Alamos National Laboratory flu web site (Macken et al., The value of a database in surveillance and vaccine selection, in Options For The Control Of Influenza IV, Osterhaus et al., (Eds.) Amsterdam: Elsevier Science, pp. 103-106, 1001). Evaluation of -gal epitope expression on flu virus propagated in Vero.sub.GT cells can be accomplished using the methods of experimental example 1 and as shown in
[0071] Since birds lack -gal epitopes (Galili et al., J Biol Chem 263:17755, 1988) and naturally produce anti-Gal (Cotter et al., Poult Sci 85:435, 2006; and McKenzie et al., Transplantation 67:864, 1999), efficient anti-Gal mediated targeting of flu.sub.gal virus produced in Vero.sub.GT cells to APC of avian vaccine recipients is also contemplated to occur. Thus, the flu.sub.gal virus produced using the methods of the present invention is contemplated to be suitable vaccine for delivery to birds (e.g., including but not limited to chickens, turkeys, ducks and geese). Immunization of bird flocks with H5N1 flu.sub.gal virus (vaccine target strain such as A/Bar headed goose/Qinghai/1A/2005 or A/Whooping swan/Mongolia/244/2005) is contemplated to reduce circulation of avian influenza viruses in bird populations, which in turn is contemplated to reduce the spread of avian influenza viruses to humans.
[0072] IV. Hemagglutainin Expressing -Gal Epitopes (HA.sub.gal) as a Vaccine Platform
[0073] As described herein the present invention also provides compositions and methods for production of fusion proteins comprising an HA component bearing -gal epitopes (HA.sub.gal) and a non-HA component (e.g., microbial protein or polypeptide antigen of interest) to increase opsonization of the non-HA component thereby increasing the immunogenicity of the non-HA component. In some preferred embodiments, the fusion protein comprises an HA component bearing -gal epitopes (HA.sub.gal) as a platform for anti-Gal mediated targeting to APC of one or both of the M2e peptide of the conserved flu virus matrix protein 2 (M2) peptide and the conserved flu virus nucleoprotcin (NP). The HA.sub.gal-M2e and HA.sub.gal-NP fusion proteins are contemplated to be suitable for achieving a broad cross protective immune response against various influenza virus strains. In an exemplary embodiment, HA of avian influenza virus H5N1 is employed (influenza A virus A/Vietnam/CL2009/2005, GENBANK Accession No. DQ497729.1). Other suitable HA sequences are listed in the influenza sequence database accessible through the Los Alamos National Laboratory flu web site (Macken et al., The value of a database in surveillance and vaccine selection, in Options For The Control Of Influenza IV, Osterhaus et al., (Eds.) Anmsterdam: Elsevier Science, pp. 103-106, 2001).
[0074] The high mutation rate in HA reduces its suitability for use as vaccine for induction of broad protection against multiple flu virus strains. In contrast, the viral proteins M2 and NP are highly conserved as they undergo very low rates of mutation (Flynn et al., Proc Natl Acad Sci USA 96:8597, 1999; and Webster, Vaccine 18:1686, 2000). The M2 protein is abundant in the cell membrane of flu virus infected cells, but comprises <2% of proteins on the virus envelope (Mozdzanowska et al, Vaccine 21: 2616, 2003). Anti-M2e antibodies can target the outer region of M2 (23 amino acid ectodomain called M2c) expressed on the surface of flu virus-infected cells. These antibodies can mediate destruction of virus-infected cells through antibody-dependent cell-mediated cytotoxicity (ADCC). Similarly, effective induction of cytotoxic T lymphocytes (CTL) reactive with NP peptides presented on MHC class I molecules of flu virus-infected cells can mediate the killing of flu virus-infected cells. Effective anti-M2e antibody responses and anti-NP CTL responses are contemplated to contribute significantly to prevention of viral spread in the infected individual by these two mechanisms of antibody-mediated, or cell-mediated destruction of flu virus infected cells.
[0075] Previously, immunogenicity of recombinant M2e and NP was found to be very low (Mozdzanowska et al., Vaccine 21: 2616, 2003; and Zhang et al., Mol Immunol 43: 2195, 2006). This low immunogenicity is associated with suboptimal uptake of M2e and NP molecules by APC at the inoculation site. As described herein the present invention provides methods and compositions for induction of potent antibody responses against flu virus-infected cells expressing the M2e peptide and/or CTL responses against flu virus-infected cells presenting NP peptides in the context of MHC class I molecules. In some embodiments this is accomplished by generating recombinant fusion proteins between HA and M2e and between HA and NP, synthesis of -gal epitopes on the multiple carbohydrate chains of the HA component, and the use of the HA.sub.gal component of the fusion protein as a platform for anti-Gal mediated targeting of M2e and/or NP to APC. In immunogens containing a HA.sub.gal component, endogenous anti-Gal antibodies of a recipient bind to -gal epitopes on the HA component to target the M2e and/or NP components of the fusion proteins to APC.
[0076] A process for achieving expression of -gal epitopes on flu virus by in vitro incubation with recombinant 1,3GT and with UDP-Gal has been described in U.S. Pat. Nos. 5,879,675 and 6,361,775 to Galili et al., herein incorporated by reference in their entirety. However, the prior art patents did not disclose the use of HA.sub.gal as platform for targeting other microbial antigens to APC. In exemplary embodiments, HA is fused to M2e or NP to generate recombinant fusion proteins HA-M2e or HA-NP, as shown in
[0077] The HA-M2e and HA-NP fusion proteins are subsequently incubated with neuraminidase from Vibrio cholera and recombinant 1,3GT and with UDP-Gal to produce fusion proteins bearing -gal epitopes on the amino-terminal HA component. Examples of HA-M2e and HA-NP production are included herein as Examples 6 and 7 respectively. The -gal epitopes of the HA component are bound by anti-Gal of the recipient for targeting of the fusion proteins to APC, thereby increasing the immunogenicity of M2e and NP for eliciting a broad cross-protective immune response against infectious flu virus (See, illustration in
[0078] HA of flu virus has at least 6 asparagine (N)-linked carbohydrate chains, which when produced in CHO cells have the structure identical to the left-most carbohydrate chain in
[0079] Since birds lack -gal epitopes (Galill et al., J Biol Chem 263:17755, 1988) and naturally produce anti-Gal (Cotter et al., Poult Sci 85:435, 2006; and McKenzie et al., Transplantation 67:864, 1999), efficient anti-Gal mediated targeting of HA.sub.gal-M2e or HA.sub.gal-NP to APC of avian vaccine recipients is also contemplated to occur. Thus, the HA.sub.gal-M2e or HA.sub.gal-NP fusion proteins produced using the methods of the present invention are contemplated to be suitable vaccine for delivery to birds (e.g., including but not limited to chickens, turkeys, ducks and geese). Immunization of bird flocks with H5-based HA.sub.gal-M2e or HA.sub.gal-NP fusion proteins is contemplated to reduce circulation of avian influenza viruses in bird populations, which in turn is contemplated to reduce the spread of avian influenza viruses to humans.
[0080] In further embodiments, synthesis of -gal epitopes on the carbohydrate chains of HA-M2e or HA-NP is achieved by expression in host cells lacking the ability to add sialic acid caps to glycoproteins but having the ability to synthesize -gal epitopes. Briefly, expression vectors comprising the fusion genes in operable combination with a promoter are transfected into host cells of a non-primate mammal having a defect in the cellular machinery required for sialic acid capping of carbohydrates to produce HA.sub.gal-M2e, or NA.sub.gal-NP without having to treat the recombinant fusion proteins in vitro with a combination of neuraminidase, 1,3GT and UDP-Gal. In some embodiments, the cells defective in the ability to add sialic acid caps are LEC29. Lec32 cells obtained from a mutagenized population of CHO cells following selection with wheat germ agglutinin as previously described (Potvin et al., J Biol Chem, 270:30415-30421, 1995). In alternative embodiments, the cells defective in the ability to add sialic acid caps are other mutant cells of the prior art (Potvin et al., supra, 1995).
[0081] In still further embodiments, synthesis of -gal epitopes on the carbohydrate chains of HA-M2e or HA-NP is achieved by expression in transgenic host cells having the ability to remove sialic acid caps from nascent glycoproteins, as well as the ability to synthesize -gal epitopes. Briefly expression vectors comprising the fusion genes in operable combination with a promoter are transfected into transgenic host cells of a non-primate mammal comprising an expression vector comprising a flu neuraminidase gene in operable combination with a promoter to produce HA.sub.gal-M2e, or NA.sub.gal-NP, without having to treat the recombinant fusion proteins in vitro with a combination of neuraminidase, 1,3GT and UDP-Gal. In some embodiments, the transgenic host cells are MDCK cells (ATCC No. CCL-34) or NIH/3T3 cells (ATCC No. CCL-1658) engineered to express a flu neuraminidase gene. In further embodiments, the transgenic host cells lack endogenous 1,3GT activity, such as Vero cells (ATCC No. CCL-81) or CHO cells, and are therefore transfected with one or more expression vectors comprising a flu neuraminidase gene and a functional 1,3GT gene. Production of HA.sub.gal-M2e, or NA.sub.gal-NP in such transgenic cells is achieved without having to treat the recombinant fusion proteins in vitro with a combination of neuraminidase, 1,3GT and UDP-Gal. In some particularly preferred embodiments, a single expression vector drives expression of the heterologous neuraminidase and 1,3GT genes from a single promoter by separation of the genes with an internal ribosomal entry site (IRES).
[0082] The previous description uses HA as an exemplary glycoprotein carrier. However, other proteins comprising one or more N-linked glycosylation sites may be employed as the amino-terminal component of an immunogenic fusion protein. Other suitable glycoprotein carriers include but are not limited to HIV gp120 (Abdel-Motal et al. J Virol. 80:6943-6951), human hepatitis B surface antigen, and human alpha-1 acid glycoprotein (AGP), and human laminin. In still further embodiments, an artificial polypeptide (GGGNGSGGGNGTGGGNGSGGGNGTGGG set forth as SEQ ID NO: 12) comprising multiple (e.g., 4) N-linked glycosylation sites is utilized as a glycoprotein carrier. In preferred embodiments, the glycoprotein carrier comprises at least two and more preferably from two to ten (e.g., two, three, four, five, six, seven, eight, nine or ten) N-linked glycosylation sites defined as NXS/T, wherein N is asparagine, X is any amino acid except proline, S is serine and T is threonine.
[0083] The artificial polypeptide can be recombinantly produced by expression behind a leader sequence and in front of microbial polypeptide of interest. Alternatively, the artificial polypeptide can be produced synthetically, chemically conjugated to a microbial polypeptide of interest, and treated with neuraminidase, 1,3GT and UDP-Gal in vitro to produce an immunogen bearing -gal epitopes. Similarly, the artificial polypeptide-microbial polypeptide fusion can be produced synthetically and treated with neuraminidase, 1,3GT and UDP-Gal in vitro to produce an immunogen bearing -gal epitopes. Likewise, a microbial polypeptide such as M2e (SEQ ID NO:10) can be produced synthetically, chemically conjugated to a purified glycoprotein such as AGP (Tanemura et al., Transplantation, 73:1859-1868, 2002), and treated with neuraminidase, 1,3GT and UDP-Gal in vitro to produce an immunogen bearing -gal epitopes. In still further embodiments, other types of N-linked carriers are employed. For instance, -gal epitopes can be synthesized on backbones such as gas914 and polyethylene glycol (Zhong et al., Transplantation, 75:10-19, 2003; and Diamond et al., Transplantation, 73:1780-1787, 2002), which subsequently can be chemically conjugated to a microbial polypeptide of interest.
EXPERIMENTAL
[0084] The following examples are provided in order to demonstrate and further illustrate certain preferred embodiments and aspects of the present invention and are not to be construed as limiting the scope thereof.
[0085] In the experimental disclosure which follows, the following abbreviations apply: kDa (kilodalton); rec. (recombinant); N (normal); M (molar); mM (millimolar); M (micromolar); mol (moles); mmol (millimoles); pmol (micromoles); nmol (nanomoles); pmol (picomoles); g (grams); mg (milligrams); g (micrograms); ng (nanograms); l or L (liters); ml (milliliters); l (microliters); cm (centimeters); mm (millimeters); m (micrometers); nm (nanometers); C (degrees Centigrade); ELISA (enzyme linked immunosorbent assay); mAb (monoclonal antibody); APC (antigen presenting cell); CTL (cytotoxic T lymphocyte); DC (dendritic cells); flu (influenza); HA (hemagglutinin); hemagglutination units (HAU); NA (neuraminidase); NP (nucleoprotein); PR8 (A/Puerto Rico/8/34-H1N1); Th (helper T); and IFN (interferon-).
Example 1
In Vitro Synthesis of -Gal Epitopes to Produce PR8.SUB.gal
[0086] This example describes the synthesis of -gal epitopes in the experimental flu virus strain A/Puerto Rico/8/34-H1N1 (PR8). This example is also applicable to the synthesis of -gal epitopes on the fusion proteins HA-M2e and HA-NP to generate fusion proteins HA.sub.gal-M2e and/or HA.sub.gal-NP, which are contemplated to induce broad cross-protective immune responses against flu virus infection when used in vaccine formulations.
[0087] The PR8 virus produced in embryonated eggs was incubated with 30 g/ml of recombinant (rec.) 1,3GT and 0.1 mM UDP-Gal (uridine diphosphate-galactose) as a sugar donor. The enzyme transfers the galactose from UDP-Gal and links it in a Gal1-3 linkage to the N-acetyllactosamines (Gal1-4GlcNAc-R) of the multiple HA carbohydrate chains to generate -gal epitopes, in a reaction that is identical to that naturally occurring within the Golgi apparatus of non-primate mammalian cells (middle chain to right chain in
[0088] The de-novo synthesized -gal epitopes on PR8 could be detected by Western blot (
[0089] Additionally, expression of -gal epitopes on PR8.sub.gal was demonstrated on the intact virus as determined by ELISA with the anti-Gal mAb M86 and intact viruses as solid phase antigens. As shown in
Example 2
ELISPOT Analysis of T Cell Responses in Mice Immunized with PR8.SUB.gal .or PR8
[0090] The T cell response to flu virus antigens following vaccination with PR8.sub.gal virus in comparison to vaccination with PR8 virus was studied in the experimental animal model, the 1,3GT knockout mice (KO mice) in which the exon containing the catalytic domain of the enzyme was disrupted by insertion of a neomycin resistance gene (Thall et al., J Biol Chem 2170:21437, 1995). The KO mice effectively produce anti-Gal after 3-4 immunizations with pig kidney membrane (PKM) homogenates. The characteristics of this anti-Gal are very similar to those of human anti-Gal (Abdel-Motal et al., J Virol. 80: 6943, 2006). KO mice producing anti-Gal were immunized twice in bi-weekly intervals with 1 g inactivated PR8.sub.gal virus or with inactivated PR8 virus. The inactivation was achieved by incubation of the viruses for 45 min at 64 C., and confirmed by demonstration of a complete loss of chicken red blood cell (ChRBC) hemagglulinating activity. The inactivated virus was injected subcutaneously in Ribi (trehalose dicorynomycolate) adjuvant.
[0091] The mice were studied for anti-PR8 immune response 4 weeks after the second immunization. PR8-specific T cells were detected in the spleens of the immunized mice by ELISPOT assays, which measured secretion of interferon- (IFN) following stimulation in vitro by PR8 antigens presented on dendritic cells (DC). Briefly, KO mouse DC were incubated for 24 h with inactivated PR8, then co-incubated for an additional 24 h with spleen lymphocytes from the mice immunized with PR8.sub.gal or PR8 virus. PR8-specific T cells stimulated by DC presenting immunogenic PR8 peptides, secrete IFN, which binds to the anti-IFN antibody coating the bottom of the ELISPOT well at the secretion site. After washing the wells, the site of the secreting T cell is detected as a spot by alkaline phosphatase coupled anti-IFN antibody. The number of T cells that secrete IFN in the absence of stimulatory PR8 did not exceed 50 per 10.sup.6 lymphocytes in any of the mice tested (open columns in
Example 3
Increased PR8 Specific CD8+ and CD4+ T Cell Responses Following PR8.SUB.gal .Immunization as Measured by Intracellular Cytokine Staining (ICS)
[0092] In order to determine whether the virus specific T cells in mice immunized with PR8 or PR8.sub.gal include both CD8+ T cells (CTL precursors) and CD4+ T cells (Th1 cells) intracellular cytokine staining (ICS) methods were employed. Briefly, the ICS methods utilized involved the detection of IFN production in activated T cells that were also stained with CD8 or CD4 specific antibodies. The spleen lymphocytes from immunized mice were co-incubated for 24 h with DC that process PR8 proteins (due to pulsing with PR8) as in the ELISPOT assays above. However, cytokine secretion was prevented by treatment with brefeldin. Subsequently, the cells were washed, permeabilized and stained for intracellular IFN using a labeled anti-IFN antibody and an anti-CD8 or an anti-CD4 antibody. As shown in
[0093] The differential response of T cells to the PR8 peptides presented by DC was also observed among the CD4+ T cells. Four of the mice immunized with PR8.sub.gal displayed 12-13.7% activation of CD4+ T cells, whereas no significant activation of such cells was observed among CD4+ T cells from PR8 immunized mice (
Example 4
Increased Production of Anti-PR8 Antibodies Following PR8.SUB.gal .Immunization
[0094] This example describes the humoral immune response elicited in mice by administration of the -gal epitope-bearing influenza virus strain, PR8.sub.gal.
1. Enzyme Linked Immunosorbant Assay (ELISA).
[0095] Anti-Gal liters in mice immunized with pig kidney membrane and the level of production of anti-PR8 antibodies were determined by ELISA as previously described (Abdel-Motal et al., J Virol, 80:6943-6951, 2006). Briefly, ELISA wells were coated with -Gal BSA (10 g/ml) or PR8 virus (1 g/ml) overnight at 4 C. The plates were washed once with PBS and blocked with 1% BSA in PBS. Serum samples at various dilutions (50-l aliquots) were plated in the wells for 2 h at room temperature. After the plates were washed, HRP-coupled goat anti-mouse IgG or goat anti-mouse IgA was added for 1 h. Color reactions were developed with ortho-phenylene diamine, and absorbance was measured at 492 nm. In assays using the monoclonal anti-Gal antibody M86 (Galili et al., Transplantation, 65:1129-1132, 1998), HRP-anti-mouse IgM was used as a secondary antibody. For antibody analysis within the sera, the first dilution was 1:10, whereas for analysis of the supernatants of lung homogenates, the first dilution was 1:1.
[0096] The sera from KO mice immunized with PR8 or PR8.sub.gal were assayed for antibodies to the unprocessed PR8 virus used as solid phase antigen in an ELISA. As shown in
[0097] To determine whether the differences in antibody responses observed in the PR8 or PR8.sub.gal immunized KO mice are associated with anti-Gal, C57BL/6 wild type (WT) mice were also immunized with PR8 or PR8.sub.gal. The WT mice express -gal epitopes on their cells and thus, do not produce anti-Gal despite repeated (e.g., 4) immunizations with pig 0.32-kidney membranes (PKM). As shown in
[0098] The differential humoral immune response in KO mice immunized with PR8.sub.gal versus those immunized with PR8 is also evident by analysis of anti-PR8 IgA antibodies in an ELISA employing PR8 virus as a solid phase antigen. The significance of this immunoglobulin class is primarily in mucosal immunity that prevents viral infection of respiratory tract cells. As shown in
[0099] The anti-PR8 antibody studies indicate that flu.sub.gal virus is much more immunogenic than flu virus lacking -gal epitopes. Thus, immunization with flu.sub.gal virus induces more potent humoral as well as cellular immune responses in recipients possessing anti-Gal antibodies.
II. Hemagglutinin Inhibition (HI) Assay.
[0100] One of the distinct antibody activities that protects against infection by the influenza virus is that of antibodies binding to the HA of the infectious virus, indicated by the prevention of subsequent binding of this envelope glycoprotein to target cells for infection. The ability of anti-HA antibodies to inhibit viral agglutination of ChRBC was measured as described previously (Galili et al., Vaccine, 14:321-328, 1996). Briefly, 5 HAU/ml of PR8 virus was plated in 96-well V-bottom plates (Corning). Sera were diluted in PBS containing 0.08% sodium azide. Aliquots of sera at serial twofold dilutions (beginning with a serum dilution of 1:10) were added to the virus and incubated overnight at 4C. Subsequently, 50 l of 1% ChRBC suspension was added and incubated for 30 min at room temperature. HA inhibition (HT) titers were determined as the highest serum dilution at which the hemagglutination of ChRBC was inhibited.
[0101] The level of HI activity in PR8.sub.gal-immunized KO mice was many times higher than that in PR8-immunized mice. The average HI titer in the former group was 1:135, whereas in the latter group it was 1:15, (nine-fold lower). Two mice (#5 and #6) among the PR.sub.gal-immunized mice displayed a much lower level of HI activity, in agreement with other immune response parameters. On the other hand, the average level of HI activity in the highly responsive mice in that group (#1 to #4) is 1:180, which is 12-fold higher than in the control group immunized with unmodified PR8.
Example 5
Induction of a Protective Immune Response Against Challenge with PR8
[0102] Mice were immunized twice with 1 g of inactivated PR8 or PR8.sub.gal virus in the Ribi adjuvant at a bi-weekly interval. Four weeks after the second immunization the mice were studied for resistance to challenge with 2000 plaque-forming units (PFU) of live PR8 virus in 50 l administered via the nostrils (e.g., intranasally). Each group included 26 mice. The mice were monitored for mortality every day for 30 days post challenge.
[0103] Most mice (85%) immunized with inactivated PR8 virus were not resistant to the intranasal viral challenge and died within 10 days post challenge with the live PR8 virus. As shown in
[0104] In separate studies, mice immunized with PR8.sub.gal or PR8 were euthanized 3 days post-challenge, and their lungs were harvested and homogenized in PBS to a total volume of 1 ml. The virus titers in supernatants of the homogenate were determined by measuring the tissue culture infectious dose (TCD) in MDCK cell monolayers (e.g., determine highest dilution resulting in cytopathic effect) and the hemagglutination of ChRBC. Incubation of the virus at serial 10-fold dilutions with MDCK cells for 96 h indicated that two of the PR8.sub.gal-immunized mice had TCIDs of 100 and the remaining three mice had TCIDs of 10 (e.g., a dilution of 1:10 was the highest dilution resulting in a cytopathic effect on MDCK cells). In contrast, four of the five PR8-immunized mice had TCIDs of 1,000 and only one had a TCID of 100. The average TCID among the PR8.sub.gal-immunized mice was approximately 18-fold lower than that in PR8-immunized mice. This difference in the presence of live PR8 in the lungs of the PR8-challenged mice was confirmed by analysis of the hemagglutination titers with ChRBC. Incubation of lung homogenate supernatants from PR8.sub.gal-immunized mice with ChRBC resulted in hemagglutination titers (reciprocal of end point dilution displaying agglutination) of 50 for four mice and 100 for one mouse. In contrast, the titer for three of the PR8-immunized mice was 1,000, and for the remaining two mice it was 10,000.
[0105] One of the factors preventing virus infection and subsequent virus production in the lung cells of the PR8.sub.gal-immunized mice is likely the anti-PR8 IgA antibody activity in the lungs. The activity of these antibodies was determined with an ELISA with serial twofold dilutions of the supernatants from lung homogenates. The lung homogenates from PR8-immunized mice contained no detectable anti-PR8 IgA antibodies, whereas those from all five PR8.sub.gal-immunized mice had distinct anti-PR8 IgA activity. The lack of detectable anti-PR8 IgA antibodies in the lungs of PR8-immunized mice corresponds to the low level of such antibodies in the sera of PR8-immunized mice and suggests that the level of these antibodies in the lungs is beneath the detection level for ELISA.
Example 6
Production of a HA.SUB.gal.-M2e Fusion Protein
[0106] This example provides an exemplary method for producing a HA-M2e recombinant fusion protein for subsequent preparation of a HA.sub.gal-M2e immunogen. The steps illustrated in
[0107] The HA-M2e fusion gene is inserted into an expression vector (e.g., Invitrogen pVAX1) containing a promoter active in mammalian cells (e.g., cytomegalovirus promoter) and a selectable marker (e.g., kanamycin resistance gene). Although the exemplary embodiment comprises the leader sequence of HA, other leader sequences may be used in place of this leader sequence (e.g., secretion signal from the V-J2-C region of mouse Ig kappa chain). The plasmid transfected into a suitable host cell (e.g., Chinese hamster ovary cells) by a suitable method (e.g., electroporation), and kanamycin-resistant clones found to secrete large amounts of the HA-M2e fusion protein are selected (e.g., as determined by ELISA or western blot). After expansion of suitable clones, the fusion protein secreted from the cells into the culture medium is isolated by affinity chromatography (e.g., by binding to a nickel-sepharose column via the polyhistidine tag as previously described by Chen et al., Glycobiology 11:577, 2001). The generation of HA-M2e fusion proteins is not limited to the method described above and may be accomplished by other molecular biology methods known to those skilled in the art. Although the exemplary embodiment involves the use of culture cells for expression of the fusion protein, other types of systems may be employed in alternative embodiments (e.g., secretion into milk of transgenic animals engineered to express the fusion protein in cells of the mammary gland).
[0108] The purified fusion protein bound to nickel-Sepharose beads via the polyhistidine tag is subjected to synthesis of -gal epitopes by incubation with neuraminidase, recombinant 1,3GT and UDP-Gal. Briefly the enzymatic reactions shown in
Example 7
Production of a HA.SUB.gal.-NP Fusion Protein
[0109] This example provides an exemplary method for producing a HA-NP recombinant fusion protein for subsequent preparation of a HA.sub.gal-NP immunogen. The steps illustrated in
[0110] The HA-NP fusion gene is inserted into an expression vector (e.g., Invitrogen pVAX1) containing a promoter active in mammalian cells (e.g., cytomegalovirus promoter) and a selectable marker (e.g., kanamycin resistance gene). Although the exemplary embodiment comprises the leader sequence of HA, other leader sequences may be used in place of this leader sequence (e.g., secretion signal from the V-J2-C region of mouse Ig kappa chain). The plasmid transfected into a suitable host cell (e.g., Chinese hamster ovary cells) by a suitable method (e.g., electroporation), and kanamycin-resistant clones found to secrete large amounts of the HA-NP fusion protein are selected (e.g., as determined by ELISA or western blot). After expansion of suitable clones, the fusion protein secreted from the cells into the culture medium is isolated by affinity chromatography (e.g., by binding to a nickel-sepharose column via the polyhistidine tag as previously described by Chen et al., Glycobiology 11:577-586, 2001). The generation of HA-NP fusion proteins is not limited to the method described above and may be accomplished by other molecular biology methods known to those skilled in the art. Although the exemplary embodiment involves the use of culture cells for expression of the fusion protein, other types of systems may be employed in alternative embodiments (e.g., secretion into milk of transgenic animals engineered to express the fusion protein in cells of the mammary gland).
[0111] The purified fusion protein bound to nickel-Sepharose beads via the polyhistidine tag is subjected to synthesis of -gal epitopes by incubation with neuraminidase, recombinant 1,3GT and UDP-Gal. Briefly the enzymatic reactions shown in
[0112] All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention, which are obvious to those skilled in the relevant fields are intended to be within the scope of the following claims.